Company intelligence / Profile preview
Transneural Therapeutics
Seattle Metro Area, Washington, United Statestransneural.com ↗
- Ownership
- Private
- Development stage
- Preclinical
01
Overview
Transneural Therapeutics is a preclinical-stage biotech developing non-hallucinogenic neuroplastogens as potential best-in-class treatments for major depressive disorder and post-traumatic stress disorder. Their lead candidate, TN-001, is a dual 5‑HT2A partial agonist/5‑HT2B antagonist designed to promote rapid antidepressant-associated neuroplasticity without hallucinations or dissociative effects. The company’s approach aims to deliver efficacy comparable to psychedelic therapies with improved safety and outpatient accessibility. Clinical trials have not yet begun; all programs remain in preclinical development.
- Therapeutic areas
- Psychiatry
- Modalities
- Small moleculeNeuroplastogen
- Industry
- Biotech
02
Drug pipeline
2 assets1 more asset in the full pipeline.
03
Partnerships
CaaMTech (seed financing)
Beyond the preview
Go deeper on Transneural Therapeutics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Transneural Therapeutics.